Cargando…

GLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?

Hyperglycemia strongly affects endothelial function and activation, which in turn increases the risk of atherosclerotic cardiovascular disease. Among pharmacotherapies aimed at lowering blood glucose levels, glucagon-like peptide 1 receptor agonists (GLP-1RA) represent a class of drugs involved in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Menghini, Rossella, Casagrande, Viviana, Rizza, Stefano, Federici, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520195/ https://www.ncbi.nlm.nih.gov/pubmed/37401947 http://dx.doi.org/10.1007/s00592-023-02124-w

Ejemplares similares

TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy
por: Casagrande, Viviana, et al.
Publicado: (2021)

Restoration of renal TIMP3 levels via genetics and pharmacological approach prevents experimental diabetic nephropathy
por: Casagrande, Viviana, et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma
por: Casagrande, Viviana, et al.
Publicado: (2017)

TIMP3 interplays with apelin to regulate cardiovascular metabolism in hypercholesterolemic mice
por: Stöhr, Robert, et al.
Publicado: (2015)

TIMP3 Is Reduced in Atherosclerotic Plaques From Subjects With Type 2 Diabetes and Increased by SirT1
por: Cardellini, Marina, et al.
Publicado: (2009)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2018)

Impact of Insulin Degludec/Liraglutide Fixed Combination on the Gut Microbiomes of Elderly Patients With Type 2 Diabetes: Results From A Subanalysis of A Small Non-Randomised Single Arm Study
por: Rizza, Stefano, et al.
Publicado: (2023)

Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
por: Heile, Michael, et al.
Publicado: (2018)

MicroRNA 221/222 cluster kicks out Timp-3 to inflame the liver
por: Menghini, Rossella, et al.
Publicado: (2018)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca(2+)‐activated K(Ca)3.1 channels
por: Cocozza, Germana, et al.
Publicado: (2021)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
por: Kalra, Sanjay, et al.
Publicado: (2021)

TIMP3 Overexpression in Macrophages Protects From Insulin Resistance, Adipose Inflammation, and Nonalcoholic Fatty Liver Disease in Mice
por: Menghini, Rossella, et al.
Publicado: (2012)

The Endothelium Abridges Insulin Resistance to Premature Aging
por: Avogaro, Angelo, et al.
Publicado: (2013)

Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes
por: Longo, Susanna, et al.
Publicado: (2023)

Correction to: GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
por: Sposito, Andrei C., et al.
Publicado: (2019)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Androgen actions on endothelium functions and cardiovascular diseases
por: Cai, Jing-Jing, et al.
Publicado: (2016)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice
por: Romera, Irene, et al.
Publicado: (2023)

Morphological and Functional Remodeling of Vascular Endothelium in Cardiovascular Diseases
por: Bkaily, Ghassan, et al.
Publicado: (2023)

The efficacy of GLP‐1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review
por: Llewellyn, David C., et al.
Publicado: (2022)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

COVID-19–Associated Endothelial Dysfunction and Microvascular Injury: From Pathophysiology to Clinical Manifestations
por: Canale, Maria Paola, et al.
Publicado: (2022)

Protective Effects of GLP-1 on Glomerular Endothelium and Its Inhibition by PKCβ Activation in Diabetes
por: Mima, Akira, et al.
Publicado: (2012)

Decreased IRS2 and TIMP3 Expression in Monocytes From Offspring of Type 2 Diabetic Patients Is Correlated With Insulin Resistance and Increased Intima-Media Thickness
por: Cardellini, Marina, et al.
Publicado: (2011)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Effectiveness of SGLT2is vs. GLP-1RAs on cardiovascular and cerebrovascular outcomes in T2D patients according to CVD status
por: Du, Lixin, et al.
Publicado: (2022)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
por: del Olmo-Garcia, María Isabel, et al.
Publicado: (2018)

Role of Endothelium in Cardiovascular Sequelae of Long COVID
por: Santoro, Luca, et al.
Publicado: (2023)

The Role of GLP1-RAs in Direct Modulation of Lipid Metabolism in Hepatic Tissue as Determined Using In Vitro Models of NAFLD
por: Petrovic, Ana, et al.
Publicado: (2023)

Loss of TIMP3 underlies diabetic nephropathy via FoxO1/STAT1 interplay
por: Fiorentino, Loredana, et al.
Publicado: (2013)

Endothelium and Its Alterations in Cardiovascular Diseases: Life Style Intervention
por: Favero, Gaia, et al.
Publicado: (2014)

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
por: Lv, Xiaodan, et al.
Publicado: (2020)

Weight Loss Effect of GLP-1 RAs With Endoscopic Bariatric Therapy and Bariatric Surgeries
por: Imam, Ahmad, et al.
Publicado: (2023)

Alterations in Rev-ERBα/BMAL1 ratio and glycated hemoglobin in rotating shift workers: the EuRhythDia study
por: Rizza, Stefano, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_smnme57cnl1dceeadjj5ve4r3a